{"id":665265,"date":"2023-08-28T14:36:01","date_gmt":"2023-08-28T14:36:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=665265"},"modified":"2023-08-28T14:36:01","modified_gmt":"2023-08-28T14:36:01","slug":"propulsion-of-pd1-nonsmall-cell-lung-cancer-clinical-trial-pipeline-as-novel-and-extensive-30-therapies-likely-to-enter-in-the-domain-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/propulsion-of-pd1-nonsmall-cell-lung-cancer-clinical-trial-pipeline-as-novel-and-extensive-30-therapies-likely-to-enter-in-the-domain-delveinsight_665265.html","title":{"rendered":"Propulsion of PD-1 Non-Small Cell Lung Cancer Clinical Trial Pipeline as Novel and Extensive 30+ Therapies Likely to Enter in the Domain | DelveInsight"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1693206523.png\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Propulsion of PD-1 Non-Small Cell Lung Cancer Clinical Trial Pipeline as Novel and Extensive 30+ Therapies Likely to Enter in the Domain | DelveInsight \" src=\"https:\/\/www.abnewswire.com\/uploads\/1693206523.png\" alt=\"Propulsion of PD-1 Non-Small Cell Lung Cancer Clinical Trial Pipeline as Novel and Extensive 30+ Therapies Likely to Enter in the Domain | DelveInsight \" width=\"225\" height=\"225\" \/><\/a><\/div>\n<p style=\"text-align: justify;\">(Albany, United States) As per DelveInsight&rsquo;s assessment, globally, the PD-1 Non-Small Cell Lung Cancer Pipeline constitutes 30+ key companies continuously working towards developing 30+ PD-1 Non-Small Cell Lung Cancer Pipeline treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">In the PD-1 Non-Small Cell Lung Cancer Pipeline Report, a detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, PD-1 Non-Small Cell Lung Cancer NDA approvals (if any), and product development activities comprising the technology, PD-1 Non-Small Cell Lung Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>To explore more information on the latest breakthroughs in the PD-1 Non-Small Cell Lung Cancer Pipeline treatment landscape of the report, click here @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/pd-1-non-small-cell-lung-cancer-pd-1-nsclc-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">PD-1 Non-Small Cell Lung Cancer Pipeline Outlook<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Key Takeaways from the PD-1 Non-Small Cell Lung Cancer Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>DelveInsight&rsquo;s PD-1 Non-Small Cell Lung Cancer Pipeline analysis depicts a robust space with 30+ active players working to develop 30+ pipeline treatment therapies.<\/li>\n<li>The leading companies in the PD-1 Non-Small Cell Lung Cancer market include Novartis Pharmaceuticals, Merck Sharp &amp; Dohme, Navire Pharma Inc., AbbVie, BioNTech SE, Avistone Biotechnology Co., Ltd., Daiichi Sankyo Inc., Arcus Biosciences Inc., IO Biotech, Cellular Biomedicine Group Inc., and others.<\/li>\n<li>Promising PD-1 Non- Small Cell Lung Cancer Pipeline Therapies in the various stages of development include Gotistobart, Docetaxel, REGN2810, Chemotherapy, CV301, Pembrolizumab, Nivolumab, Cyclophosphamide, AZD9150, AZD6738, and others.<\/li>\n<li>On July 2023, OncoC4 Inc. announced a study of phase 3 clinical trials for Gotistobart and Docetaxel. The goal of this Phase 3 clinical trial is study the safety and efficacy of the nextgen anti-CTLA-4 antibody, gotistobart (ONC-392\/BNT316), in patients with metastatic non-small cell lung cancer who have disease progressed on anti-PD-1\/PD-L1 antibody based therapy. The study will test whether gotistobart, in comparison with chemotherapy agent docetaxel, could prolong the life for NSCLC patients.<\/li>\n<li>On August 2023, Regeneron Pharmaceuticals announced a study of phase 3 clinical trials for REGN2810 and Chemotherapy. To compare the overall survival (OS) of cemiplimab\/chemo-f and cemiplimab\/chemo-l\/ipi versus platinum-based doublet chemotherapy in the first-line treatment of patients with advanced squamous or non-squamous non-small cell lung cancer (NSCLC) with tumors expressing PD-L1 in &lt;50% of tumor cells.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>PD-1 Non-Small Cell Lung Cancer Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">Lung cancer is a type of cancer that starts in the lungs. Cancer starts when cells in the body begin to grow out of control. About 80% to 85% of lung cancers are Non-Small Cell Lung Cancer. The main subtypes of Non-Small Cell Lung Cancer are adenocarcinoma, squamous cell carcinoma, and large cell carcinoma.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>For further information, refer to the detailed PD-1 Non-Small Cell Lung Cancer Unmet Needs, click here for <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/pd-1-non-small-cell-lung-cancer-pd-1-nsclc-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">PD-1 Non-Small Cell Lung Cancer Ongoing Clinical Trial Analysis<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>PD-1 Non-Small Cell Lung Cancer Emerging Drugs Profile<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Tislelizumab (BGB-A317) &#8211; BeiGene<\/li>\n<li>Canakinumab: Novartis Pharmarmaceutical<\/li>\n<li>PLB-1004: Avistone Biotechnology<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>PD-1 Non-Small Cell Lung Cancer Pipeline Therapeutics Assessment<\/strong><\/p>\n<p style=\"text-align: justify;\">There are approx. 30+ key companies which are developing the therapies for PD-1 Non-Small Cell Lung Cancer. The companies which have their PD-1 Non-Small Cell Lung Cancer drug candidates in the most advanced stage, i.e. phase III include, Novartis Pharmaceutical.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request a sample and discover the recent advances in PD-1 Non-Small Cell Lung Cancer Ongoing Clinical Trial Analysis and Medications, Click here for more details @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/pd-1-non-small-cell-lung-cancer-pd-1-nsclc-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">PD-1 Non-Small Cell Lung Cancer Segmentation<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>PD-1 Non-Small Cell Lung Cancer Drugs and Companies<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Gotistobart: OncoC4 Inc.<\/li>\n<li>Docetaxel: BioNTech SE<\/li>\n<li>REGN2810: Regeneron Pharmaceuticals<\/li>\n<li>Chemotherapy: Sanofi<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>PD-1 Non-Small Cell Lung Cancer Therapeutics Assessment<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Assessment by Stage and Product Type<\/li>\n<li>Assessment by Route of Administration<\/li>\n<li>Assessment by Stage and Route of Administration<\/li>\n<li>Assessment by Molecule Type<\/li>\n<li>Assessment by Stage and Molecule Type<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of the Companies in the PD-1 Non-Small Cell Lung Cancer Therapeutics Market include-<\/strong><\/p>\n<p style=\"text-align: justify;\">Novartis Pharmaceuticals, Merck Sharp &amp; Dohme, Navire Pharma Inc., AbbVie, BioNTech SE, Avistone Biotechnology Co., Ltd., Daiichi Sankyo Inc., Arcus Biosciences Inc., IO Biotech, Cellular Biomedicine Group Inc., and others.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Dive deep into rich insights for drugs for PD-1 Non-Small Cell Lung Cancer Pipeline, click here @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/pd-1-non-small-cell-lung-cancer-pd-1-nsclc-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">PD-1 Non-Small Cell Lung Cancer Unmet Needs and Analyst Views<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the PD-1 Non-Small Cell Lung Cancer Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Coverage- Global<\/li>\n<li>Companies- Novartis Pharmaceuticals, Merck Sharp &amp; Dohme, Navire Pharma Inc., AbbVie, BioNTech SE, Avistone Biotechnology Co., Ltd., Daiichi Sankyo Inc., Arcus Biosciences Inc., IO Biotech, Cellular Biomedicine Group Inc., and others.<\/li>\n<li>Therapies- Gotistobart, Docetaxel, REGN2810, Chemotherapy, CV301, Pembrolizumab, Nivolumab, Cyclophosphamide, AZD9150, AZD6738, and others.<\/li>\n<li>Segmentation: Product Type, Molecule Type, Route of Administration<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Got Queries? Find out the related information on <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/pd-1-non-small-cell-lung-cancer-pd-1-nsclc-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">PD-1 Non-Small Cell Lung Cancer Merger and acquisitions, Licensing Activities<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Content<\/strong><\/p>\n<ol style=\"text-align: justify;\" start=\"1\">\n<li>Introduction<\/li>\n<li>Executive Summary<\/li>\n<li>PD-1 Non-Small Cell Lung Cancer: Overview<\/li>\n<li>Pipeline Therapeutics<\/li>\n<li>Therapeutic Assessment<\/li>\n<li>PD-1 Non-Small Cell Lung Cancer&ndash; DelveInsight&rsquo;s Analytical Perspective<\/li>\n<li>Late Stage Products (Phase III)<\/li>\n<li>Canakinumab: Novartis<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Mid Stage Products (Phase II)<\/li>\n<li>MK-5890: Merck Sharp &amp; Dohme<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Early Stage Products (Phase I)<\/li>\n<li>BBP-398: Navire Pharma Inc.<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Preclinical and Discovery Stage Products<\/li>\n<li>Drug name: Company name<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Inactive Products<\/li>\n<li>PD-1 Non-Small Cell Lung Cancer Key Companies<\/li>\n<li>PD-1 Non-Small Cell Lung Cancer Key Products<\/li>\n<li>PD-1 Non-Small Cell Lung Cancer- Unmet Needs<\/li>\n<li>PD-1 Non-Small Cell Lung Cancer- Market Drivers and Barriers<\/li>\n<li>PD-1 Non-Small Cell Lung Cancer- Future Perspectives and Conclusion<\/li>\n<li>PD-1 Non-Small Cell Lung Cancer Analyst Views<\/li>\n<li>PD-1 Non-Small Cell Lung Cancer Key Companies<\/li>\n<li>Appendix<\/li>\n<\/ol>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About Us<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&amp;D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers and acquisitions.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Yash Bhardwaj<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=propulsion-of-pd1-nonsmall-cell-lung-cancer-clinical-trial-pipeline-as-novel-and-extensive-30-therapies-likely-to-enter-in-the-domain-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304  S. Jones Blvd #2432<br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/consulting-services\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/consulting-services<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/consulting-services\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=propulsion-of-pd1-nonsmall-cell-lung-cancer-clinical-trial-pipeline-as-novel-and-extensive-30-therapies-likely-to-enter-in-the-domain-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>(Albany, United States) As per DelveInsight&rsquo;s assessment, globally, the PD-1 Non-Small Cell Lung Cancer Pipeline constitutes 30+ key companies continuously working towards developing 30+ PD-1 Non-Small Cell Lung Cancer Pipeline treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/propulsion-of-pd1-nonsmall-cell-lung-cancer-clinical-trial-pipeline-as-novel-and-extensive-30-therapies-likely-to-enter-in-the-domain-delveinsight_665265.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[405,406,413],"tags":[],"class_list":["post-665265","post","type-post","status-publish","format-standard","hentry","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/665265","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=665265"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/665265\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=665265"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=665265"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=665265"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}